ClinicalTrials.gg
RecruitingNCT07192458Updated Oct 21, 2026

High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)

A Phase 2 interventional study of Fluzone High Dose Inactivated Influenza Vaccine and Fluzone Standard Dose Inactivated Influenza Vaccine in Immunization; Infection|Transplantation Infection|Influenza and Influenza, sponsored by Vanderbilt University Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Vanderbilt University Medical Center · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 966 studies in Influenza, Human with a site in United States — 60 open to participants now, 85 under way, 7 of them phase 3. Influenza, Human · United States.

Planned enrollment
640th of 843
60 · median 270
Started
2025
with 28 others
Phase 2
161 of 966
7 open now
Primary completion
2028-12
later than 73 of 83 live
Registered
937th of 966
by date

Among the 966 studies in Influenza, Human with a site in United States, this one is the 640th largest by planned enrollment of the 843 interventional ones that give a count, is one of 29 that started in 2025, is one of 161 in phase 2, reaches primary completion later than 73 of the 83 other live ones, and was the 937th registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

60 of the 966 studies in Influenza, Human with a site in United States are open now. Recruiting first, the newest first:

54 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 966 studies in Influenza, Human with a site in United States, or all of them as a file.
02

Study summary

This will be a follow-up study to the "Comparison of High Dose vs. Standard Dose Influenza Vaccine in Lung Allograft Recipient" study (DMID Protocol Number 22-0014) at Vanderbilt University Medical Center.

Lung transplantation is a life-saving therapy for patients with advanced lung disease, and is also associated with an improvement in quality of life. However, due to the need for life-long immunosuppression to prevent acute cellular rejection and chronic lung allograft dysfunction ("chronic rejection"), lung transplant recipients are at risk for developing major infections. In fact, one-year survival is 85%, with infection being the leading cause of death within the first year post-transplant. We will conduct a follow-up phase II, randomized, double-blind trial to assess the impact of subsequent administration of two doses of HD-IIV compared to two doses of SD-IIV among lung recipients during the early post-transplant period. Demonstration of improved immunogenicity from two doses of HD-IIV over consecutive influenza seasons would provide potential broad benefit in reducing influenza disease and its associated complications in lung transplant recipients. Moreover, studying vaccine immunogenicity and safety in the same participants over consecutive years can provide insight into the influence of immunosuppression levels and allograft aging on vaccine-mediated immune modulation. This proposed study design will contribute significantly to influenza vaccination guidance and policy for the highly vulnerable lung transplant population. This proposed study is designed to address several key knowledge gaps in vaccine-mediated protection of lung transplant recipients against influenza:

  • Is there increased immunogenicity with administration of one or two doses of HD-IIV or SD-IIV in the subsequent season compared to two doses of HD-IIV or SD-IIV in the first season?
  • What is the durability of the humoral and cellular immune response between influenza seasons and does two doses of HD-IIV or SD-IIV sustain higher HAI titers compared to two doses of HD-IIV or SD-IIV in the first season?
  • What is the impact of maintenance immunosuppression levels on influenza vaccine immunogenicity within the same participant?
  • Will the optimal immunogenic vaccination strategy be associated with an acceptable long-term safety profile over successive influenza seasons, including injection-site and systemic reactions, allosensitization, and organ rejection?
Read the detailed description

The study is a phase II, single-center, double-blind, randomized controlled immunogenicity and safety trial comparing two doses of HD-IIV to two doses of SD-IIV over two consecutive years in lung transplant recipients. At study enrollment, following consent, participants will receive either HD-IIV or SD-IIV , with study arm assignments based on DMID protocol number 22-0014. Therefore, participants will ultimately receive four total doses of either HD-IIV or four total doses of SD-IIV over two consecutive influenza seasons.

03

Conditions studied

  • Immunization; Infection|Transplantation Infection|Influenza
  • Influenza

Keywords

  • Influenza
  • Vaccination
  • Immunization
  • Lung Transplantation
  • High Dose
  • Fluzone
  • Standard Dose
  • Influenza, Human
  • Communicable Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Lung transplant recipient who enrolled and completed Visits 1, 2, and 3 of the DMID protocol number 22-0014 during the prior 2024-2025 or 2025-2026 influenza season, respectively

    • Anticipated to be available for the duration of the study
    • Can be reached by telephone, text message, email, or electronic health record messaging

Exclusion criteria

Exclusion Criteria:

  • Recipient of multi-organ, extra-pulmonary, and/or hematopoietic stem cell transplant
  • Recipient of a re-do lung transplant
  • History of Guillain-Barre syndrome
  • History of receiving the current season's influenza vaccine prior to study enrollment and/or Visit 1 of this follow-up study
  • Pregnant person
  • Laboratory-confirmed influenza disease after September 1st in the current influenza season and before enrollment in this follow-up study (patient can still receive the second influenza vaccination despite proven influenza disease after enrollment)
  • CMVIG/IVIG/SCIG receipt within 28 days of each vaccine
  • Receipt of rituximab or other B-cell depleting antibody (including proteasome inhibitors) therapy within 3 months of 1st vaccine dose (Day 0)
  • Receipt of T-cell depleting therapies (anti-thymocyte globulin, alemtuzumab, daratumumab) between the completion of Visit 3 of the initial study and enrollment in this follow-up study
  • Investigator concern about study participation
  • Note: Criteria for temporarily delaying vaccine administration: The following conditions are temporary or self-limiting, and a participant may be included in the study once the condition has resolved, provided that the participant is otherwise eligible:

    • Fever ≥100.4ºF/38.0ºC (oral measurement), or an acute severe illness within 48 hours of enrollment
    • Receipt of any within four weeks or any inactivated vaccines within two weeks prior to potential study vaccination

No children have been enrolled in the DMID protocol number 22-0014; therefore, only adults will be enrolled in this current study

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Fluzone: Two Doses High Dose Inactivated Influenza Vaccine

    Fluzone: Two Doses of HD-IIV

    Biological: Fluzone High Dose Inactivated Influenza Vaccine

  • Experimental
    Fluzone: Two Doses Standard Dose Inactivated Influenza Vaccine

    Fluzone: Two Doses of of SD-IIV

    Biological: Fluzone Standard Dose Inactivated Influenza Vaccine

Interventions

  • BiologicalFluzone High Dose Inactivated Influenza Vaccine

    Fluzone High-Dose (Influenza Vaccine) for intramuscular use is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus- containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a split virus. The split virus containing hemagglutinin (HA) antigen is further purified and then suspended in sodium phosphate-buffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step to obtain a higher HA antigen concentration. The purified split virus from the three strains included in the vaccine are produced separately and then combined to make the trivalent formulation.

    Also known as: Fluzone High Dose

  • BiologicalFluzone Standard Dose Inactivated Influenza Vaccine

    Fluzone Standard Dose is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B virus contained in the vaccine.

    Also known as: Fluzone

06

What researchers measure

Primary outcomes

  1. Immunogenicity: Geometric Mean Titers of Influenza Vaccine Antibodies

    HAI GMT to influenza antigens four-eight weeks following the second study vaccination

    Time frame: Four-eight weeks following the second study vaccination

  2. Safety - The number of participants reporting solicited injection site reactions

    Solicited Injection-site Adverse Events Following each Vaccination Dose (Pain, Tenderness, Swelling/induration, Erythema/redness)

    Time frame: Within 7 days post vaccination

  3. Safety - The number of participants reporting systemic adverse events

    Systemic adverse events (Fatigue/malaise, headache, nausea, body ache/myalgia (not at the injection site), general activity level, vomiting, and fever)

    Time frame: Within 7 days post vaccination

Secondary outcomes

  1. The number of participants achieving seroprotection and seroconversion for influenza virus after receiving either two doses of HD-IIV or two doses of SD-IIV over two consecutive years

    Antibody titers will be measured by hemagglutination inhibition assay. Seroconversion is defined as ≥ 4-fold rise in hemagglutination inhibition assay titers. Seroprotection is defined as ≥1:40 hemagglutination inhibition assay titer.

    Time frame: Four to eight weeks after vaccination

  2. Geometric Mean Titers of Influenza Vaccine Antibodies after One or Two Doses in the Second Year

    To quantify and compare the degree to which one versus two doses of either HD-IIV or SD-IIV in the subsequent season elicits enhanced immunogenicity compared to two doses of either HD-IIV or SD-IIV in the first influenza season in lung transplant recipients. Measuring GMT 4-8 weeks after 1st and 2nd vaccine.

    Time frame: Within four to eight weeks post vaccination after 1st and 2nd vaccine

07

Study locations

1 of 1 sites recruiting
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
    Recruiting
    • Natahsa Halasa, MD, MPH · Contactnatasha.halasa@vumc.org · 6153223346
    • Shari D. Barto · Contactshari.barto@vumc.org · 615-421-0942
    • Natahsa Halasa, MD, MPH · Principal investigator
    • Anil J. Trindade, MD · Principal investigator
    • Kevin Dee, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Dec 2028, 39 months after the start.

Of 36 non-industry phase 2 interventional studies under Influenza, Human, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 56. This study's planned 39 months is above that.

Counting every sponsor, half of 122 studies reached it within 10 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2025
First posted
Sep 25, 2025
StartActual
Sep 17, 2025
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2029
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07192458
Responsible party
Natasha Halasa (Professor of Pediatric Infectious Diseases, Vanderbilt University Medical Center) — Principal investigator
First posted
Sep 25, 2025
Start date
Sep 17, 2025
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Oct 21, 2026

Study contacts

Natahsa Halasa, MD, MPH
Contact
natasha.halasa@vumc.org
615-322-2250
Shari D. Barto
Contact
shari.barto@vumc.org
615-421-0942
Natahsa Halasa, MD, MPH
principal investigator · Vanderbilt University Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion